Evidence map›Paper›PMID 21063728›Full record

ReviewEuropean journal of pediatrics2011

Clinical practice: proteinuria.

Gema Ariceta

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Retrospective evaluation of children with unilateral renal agenesis.Pediatric nephrology (Berlin, Germany) · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Relation of resistın wıth obesity and some cardiovascular risk factors in hypertensive women.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gema AricetaDivision of Pediatric Nephrology, Hospital de Cruces, School of Medicine, University of The Basque Country, P/Cruces s/n. 48903 Baracaldo, Vizcaya, Spain. m.gema.aricetairaola@osakidetza.net
Hospital de Cruces · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteinuria detection in children is a challenge. Five percent to 15% and 0.4-1% of school children present either transient (benign) or persistent increased amount of protein in urine, respectively. Persistent proteinuria constitutes not only a sign of overt kidney disease but may also be the first indicator of silent renal damage. Proteinuria is a marker for hyperfiltration in individuals with reduced nephron mass and one of the most important independent risk factor for renal disease progression as well. It constitutes the single most important risk factor for future loss of kidney function, preceding glomerular filtration rate reduction. Further, proteinuria itself is diagnostic of cardiovascular disease with prognostic value and target organ involvement in high-risk populations such as diabetic, obese, hypertensive children, or those with known reduced renal mass or previous renal injury. Current strategies to prevent CKD progression, a concept known as renoprotection, are focused on reducing urinary protein excretion among other factors. Reversibility of organ damage in early stages is possible; therefore, pediatricians should screen children for proteinuria or microalbuminuria, mainly in high-risk groups.

Indexed as

Cardiovascular DiseasesChildDiabetic NephropathiesDisease ProgressionHumansKidneyKidney DiseasesPractice Guidelines as TopicProteinuriaRisk Factors

Identifiers

PMID21063728
OpenAlexW2322364069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.